Harvard Bioscience, Inc.
HBIO
$6.04
$0.030.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.27% | -131.28% | 46.06% | 95.47% | -279,766.67% |
| Total Depreciation and Amortization | 0.00% | 1.96% | -18.07% | -2.36% | -5.97% |
| Total Amortization of Deferred Charges | -28.53% | 74.79% | 70.00% | 60.31% | 33.67% |
| Total Other Non-Cash Items | -89.85% | 392.73% | -18.48% | -99.12% | 10,766.06% |
| Change in Net Operating Assets | 186.49% | -416.55% | -89.60% | -20.59% | 692.24% |
| Cash from Operations | -589.58% | -108.86% | -60.65% | -7.74% | 73.10% |
| Capital Expenditure | 5.12% | -116.91% | -132.58% | 82.65% | -70.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -29.33% | -6.38% | 2.08% | 15.29% | -3.03% |
| Cash from Investing | -3.51% | -72.13% | -49.36% | 65.89% | -46.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -3,335.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 14,900.00% | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | 47.37% | -137.50% | -- | 100.00% | 85.52% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 95.90% | -1,138.19% | 16.45% | -135.66% | -- |
| Cash from Financing | -100.37% | 291.63% | -1.59% | -4.49% | 11.27% |
| Foreign Exchange rate Adjustments | -623.26% | 151.81% | -113.13% | 86.43% | 193.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -184.36% | 387.52% | -132.96% | 31.85% | 411.93% |